Top

Published in:

01-11-2013 | Editorial

The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact

Authors: Rajesh V. Lalla, Fredrick D. Ashbury

Published in: Supportive Care in Cancer | Issue 11/2013

Excerpt

This editorial introduces the second set of articles related to the update of the clinical practice guidelines for mucositis, developed by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The first set of articles was published in a special section of the January 2013 issue of Supportive Care in Cancer. The January 2013 articles reported on the methods used, considerations driving the update of the mucositis guidelines, results related to gastrointestinal mucositis, as well as several classes of interventions for oral mucositis including oral cryotherapy, laser and other light therapy, cytokines and growth factors, and amifostine [1‐8]. In the current special section of this issue, we present the remaining articles related to this update that focus on: oral hygiene maintenance, use of several additional classes of interventions, as well as pathogenesis of mucositis and risk of oral mucositis in patients receiving targeted therapies. …

Lalla RV (2013) The MASCC/ISOO Mucositis Guidelines Update: introduction to the first set of articles. Support Care Cancer 21(1):301–302. doi:10.1007/s00520-012-1660-z PubMedCrossRef

Bowen JM, Elad S, Hutchins RD, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Support Care Cancer 21(1):303–308. doi:10.1007/s00520-012-1592-7 PubMedCrossRef

Elad S, Bowen J, Zadik Y, Lalla RV (2013) Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Support Care Cancer 21(1):309–312. doi:10.1007/s00520-012-1593-6 PubMedCrossRef

Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21(1):313–326. doi:10.1007/s00520-012-1644-z PubMedCrossRef

Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, Mori T, Osaguona A, Weikel DS, Elad S, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 21(1):327–332. doi:10.1007/s00520-012-1562-0 PubMedCrossRef

Migliorati C, Hewson I, Lalla RV, Antunes HS, Estilo CL, Hodgson B, Lopes NN, Schubert MM, Bowen J, Elad S, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):333–341. doi:10.1007/s00520-012-1605-6 PubMedCrossRef

Raber-Durlacher JE, von Bultzingslowen I, Logan RM, Bowen J, Al-Azri AR, Everaus H, Gerber E, Gomez JG, Pettersson BG, Soga Y, Spijkervet FK, Tissing WJ, Epstein JB, Elad S, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):343–355. doi:10.1007/s00520-012-1594-5 PubMedCrossRef

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (2013) Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):357–364. doi:10.1007/s00520-012-1613-6 PubMedCrossRef

Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17(1):135–144. doi:10.1634/theoncologist.2011-0111 PubMedCrossRef

10.

Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group (2010) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v261–265. doi:10.1093/annonc/mdq197 PubMedCrossRef

11.

Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM 3rd (2008) NCCN task force report. prevention and management of mucositis in cancer care. J Natl Compr Cancer Netw: JNCCN 6(Suppl 1):S1–21, quiz S22-24PubMed

12.

Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C (2008) Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 12(1):141–152. doi:10.1188/08.CJON.141-152 PubMedCrossRef

13.

Peterson DE, Bensadoun RJ, Lalla RV, McGuire DB (2011) Supportive care treatment guidelines: value, limitations, and opportunities. Semin Oncol 38(3):367–373. doi:10.1053/j.seminoncol.2011.03.005 PubMedCrossRef

14.

Gagliardi AR (2012) Translating knowledge to practice: optimizing the use of guidelines. Epidemiol Psychiatr Sci 21(3):231–236. doi:10.1017/S2045796012000212 PubMedCrossRef

15.

Boaz A, Baeza J, Fraser A, European Implementation Score Collaborative Group (2011) Effective implementation of research into practice: an overview of systematic reviews of the health literature. BMC research notes 4:212. doi:10.1186/1756-0500-4-212 PubMedCrossRef

16.

Grimshaw JM, Schunemann HJ, Burgers J, Cruz AA, Heffner J, Metersky M, Cook D, Ad Hoc Committee on Integrating Coordinating Efforts in COPD Guideline Development (2012) Disseminating and implementing guidelines: article 13 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 9(5):298–303. doi:10.1513/pats.201208-066ST PubMed

Title: The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact
Authors: Rajesh V. Lalla
Fredrick D. Ashbury
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-1924-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2013

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits

Dr. Yojiro Ota

Emerging evidence on the pathobiology of mucositis

The head and neck symptom checklist©: an instrument to evaluate nutrition impact symptoms effect on energy intake and weight loss

Challenges of accrual in supportive care trials in pediatric oncology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer